ARS Pharmaceuticals to Join 2024 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 07, 2024 -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical firm focused on empowering at-risk patients and caregivers against severe allergic reactions and potential anaphylaxis, declared its engagement in the 2024 Wedbush PacGrow Healthcare Conference. This event is scheduled to take place on August 13-14, 2024, in New York City. Representatives from the company will participate in one-on-one investor meetings on Wednesday, August 14, 2024.

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals is a biopharmaceutical organization dedicated to enabling at-risk individuals and caregivers to better safeguard themselves from severe allergic reactions that can result in anaphylaxis. The company is working on neffy (also known as ARS-1), an intranasal epinephrine product currently undergoing clinical development. This product is intended for patients and caregivers dealing with Type I allergic reactions, such as those caused by food, medications, and insect stings, which can escalate into life-threatening anaphylaxis. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!